10/02/23 4:05 PMNasdaq : XAIR conferencesBeyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceBeyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patientsRHEA-AIneutral
09/27/23 9:00 AMNasdaq : XAIR conferencesclinical trialBeyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual MeetingBeyond Cancer, Ltd. (the “Company”), an affiliate of Beyond Air, Inc. (NASDAQ:RHEA-AIneutral
09/18/23 4:05 PMNasdaq : XAIR clinical trialBeyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum DisorderNew data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor The slow-release formulation led to reversal of behavioral phenotypes and the nitrosative stress of theRHEA-AIneutral
09/07/23 7:30 AMNasdaq : XAIR Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific RegionBeyond Air, Inc. (NASDAQ: XAIR)RHEA-AIvery positive
09/06/23 7:00 AMNasdaq : XAIR conferencesBeyond Air® To Participate in the 2023 Cantor Global Healthcare ConferenceBeyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patientsRHEA-AIneutral
08/10/23 4:05 PMNasdaq : XAIR earningsBeyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in excess of $1 million in annual commercial LungFit PH contracts Secured up to $40 million in debtRHEA-AIneutral
08/07/23 4:05 PMNasdaq : XAIR clinical trialBeyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)Data to be presented at the 2023 International Society of Neurochemistry (ISN) and the European Society of Neurochemistry (ESN) meeting in Portugal Data provides further evidence that selective neuronal nitric oxide synthase (nNOS) inhibitors can play a role in the treatment of ASD PosterRHEA-AIneutral
08/01/23 4:05 PMNasdaq : XAIR conferencesBeyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology ConferenceBeyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patientsRHEA-AIneutral
07/24/23 4:05 PMNasdaq : XAIR earningsBeyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and WebcastBeyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous andRHEA-AIneutral
06/22/23 4:05 PMNasdaq : XAIR earningsBeyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive preclinical data for ultra-high concentrationRHEA-AIneutral